What Dental Practices Sell For in 2026

What dental practices sell for in 2026. EBITDA multiples and goodwill percentages by size, NHS contract transfer mechanics, and verified UK and US transactions.

Updated August 2026 · refreshed quarterly. Next scheduled review: November 2026.

The dental practice M&A market in 2026 is highly active but increasingly stratified. Following the rapid consolidation of the past decade and the subsequent interest rate correction, corporate buyers and private equity platforms have returned to the market with renewed focus, but their underwriting standards have tightened considerably. In the United Kingdom, Published market data records 1,241 practices advised on or sold with a combined value of £1.68 billion in 2025, alongside 432 formal RICS valuations worth a combined £360 million. In the United States, the DSO (Dental Support Organization) model continues its relentless expansion, with platforms like Heartland Dental surpassing 1,900 offices and PDS Health crossing the 1,000-office mark across 24 states (Becker's Dental).

For a professionally represented, multi-surgery dental practice group generating over £1M in defended EBITDA, valuations typically command a premium multiple of 8.0x to 11.0x EBITDA in both markets. However, the dental sector is unique in its valuation conventions. In the UK, the market still heavily references goodwill as a percentage of gross fee income, with NASDAL reporting overall goodwill at 119% of gross fees in Q1 2026 and independent goodwill survey data recording the highest average transaction price in a decade at £1,383,637. Understanding how to reconcile this traditional goodwill percentage with the EBITDA multiple that a corporate acquirer will actually pay, particularly after adjusting for principal clinical hours, is the single most important step in preparing a dental practice for sale.

Why Two Businesses with the Same EBITDA Sell for Very Different Multiples
The 2026 EBITDA Multiples Ladder
The Cost of Compliance: Regulatory Economics
How These Businesses Are Actually Valued
The NHS Contract: Transfer Mechanics and Their Impact on Value
What Kills the Multiple
Worked Examples: Goodwill vs EBITDA
2025 and 2026 Transactions: United Kingdom
2025 and 2026 Transactions: United States
The Buyer Universe: Who is Acquiring in 2026
Demand Drivers and Regulatory Calendar
Deal Structure: How the Consideration is Paid
Public Company Multiples
The Diligence Question Bank
The 12-Month Preparation Timeline
FAQ
Glossary
Methodology and Sources

Why Two Businesses with the Same EBITDA Sell for Very Different Multiples

In the lower mid-market, an EBITDA multiple is not a fixed commodity price. It is a quality score. A buyer evaluates the risk of those earnings continuing after the founder departs, the cost of integrating the practice into their existing infrastructure, and the growth potential of the patient base and catchment area. The framework below details the thirty factors that separate a practice commanding a 9.0x multiple from one struggling to achieve 5.0x. Every factor is anchored to the specific economics of dentistry, not generic M&A theory.

Dimension A: Financial (22% weighting)

Factor	Premium Profile	Discount Profile
Revenue growth (3-year CAGR)	Consistent 8%+ organic growth driven by patient list expansion and plan membership uptake	Flat or declining revenue; growth solely from annual fee inflation or UDA rate uplifts
Quality of earnings (adjustments as % of EBITDA)	Clean financials; add-backs limited to documented one-off events; principal replacement cost clearly stated	Heavy adjustments exceeding 30% of reported profit; aggressive personal expense add-backs
Gross margin vs niche benchmark	Top quartile for associate-led model (typically 30-40% adjusted EBITDA margin on gross fees)	Below-average margin driven by high lab costs, excessive material spend, or poor associate splits
Working capital efficiency	Strong cash conversion; low debtor days; plan income collected monthly in advance	Poor collection processes; high NHS clawback exposure; significant bad debt on private accounts
Forecast credibility (pipeline visibility)	Predictable plan membership income and contracted NHS activity providing 12-month visibility	Over-reliance on volatile, high-ticket cosmetic cases with no forward booking pipeline

Dimension B: Deal Process & Buyer Access (22% weighting)

The single cheapest dimension to move, because it requires no internal business change, only the right representation across healthcare M&A.

Factor	Premium Profile	Discount Profile
Specialist representation	Engaged a dedicated sell-side adviser with deep healthcare M&A expertise and dental sector track record	Unrepresented, or using a generalist high-street accountant with no M&A experience
Buyer access	Confidentially marketed to a curated list of 20+ pre-qualified, active DSOs, corporates and PE platforms	Listed publicly on a business-for-sale website or negotiating exclusively with one unsolicited approach
Niche expertise	Adviser understands UDA clawback mechanics, NHS contract transfer routes, principal-hour normalisation, and CQC change-of-provider timing	Adviser applies generic retail or hospitality valuation models to a clinical business
Adviser brand	Recognised and respected by corporate development teams at PortmanDentex, Rodericks, and the major DSOs	Unknown to the institutional buyer community; no prior dental transactions
Evidenced demand	Multiple strategic buyers actively competing in a structured process with clear deadlines	Single buyer with no competitive tension; protracted negotiations with no time pressure

Dimension C: Customer & Revenue (16% weighting)

Factor	Premium Profile	Discount Profile
Revenue mix (NHS / private / plan)	Highly diversified; strong mix of private fee-per-item, capitation plan income, and a manageable NHS contract	Heavy reliance on a single underperforming NHS contract or one volatile referral source
Patient retention and recall adherence	High active patient count (5,000+); excellent hygiene recall rates above 70%	High patient churn; poor recall adherence; shrinking active patient list
Plan membership income	Significant, growing capitation plan (Denplan, Practice Plan) membership exceeding 30% of revenue	Zero recurring plan income; entirely transactional fee-per-item model
Treatment mix and clinical breadth	Balanced delivery of general, preventive, hygiene, and high-margin elective treatments (implants, orthodontics)	Skewed heavily toward low-margin NHS Band 1 treatments or highly volatile cosmetic procedures
New patient flow	Strong organic acquisition (50+ new patients per month); excellent Google reviews and digital presence	Stagnant patient list; no marketing strategy; reliant on ageing demographics

Dimension D: Operations (14% weighting)

Factor	Premium Profile	Discount Profile
Surgery utilisation	High occupancy across all surgeries (85%+) with room to extend operating hours or add a chair	Surgeries sitting empty multiple days per week; significant unused capacity
Clinical throughput and hygiene programme	Optimal hygiene-to-dentist ratio (2:1 or better); strong associate productivity; low FTA rates	Inefficient scheduling; high failure-to-attend rates (above 10%); no dedicated hygiene programme
Compliance and premises condition	Clean CQC registration; full HTM 01-05 compliance; modern equipment; long lease or freehold	Regulatory concerns; significant decontamination capex backlog; outdated equipment requiring replacement
Technology and digital adoption	Fully digital workflow: intraoral scanners, CBCT, cloud-based practice management, digital radiography	Analogue processes; paper records; no digital marketing infrastructure
Subcontract dependency	Employed or long-term contracted associates with stable splits and restrictive covenants	High reliance on locums or short-term agency staff with no contractual tie-in

Dimension E: People & Organisation (13% weighting)

Factor	Premium Profile	Discount Profile
Key-person dependency (principal clinical hours)	Fully associate-led; principal performs one day or fewer of clinical work per week	Principal generates 60%+ of clinical revenue; practice cannot function without them
Management depth	Experienced practice manager handling operations, HR, compliance, and finance independently	Principal handles all administrative, HR, and compliance functions personally
Associate stability and contracts	Long-tenured associates (3+ years) with well-drafted contracts, 6-month notice periods, and restrictive covenants	High associate turnover; no restrictive covenants; associates on 3-month rolling contracts
Workforce retention	Stable nursing, reception, and support team with low turnover	High staff churn; constant recruitment challenges; agency dependency
Documentation and SOPs	Comprehensive standard operating procedures, compliance logs, training records, and clinical governance framework	All knowledge held in the principal's head; no documented processes

Dimension F: Strategic (13% weighting)

Factor	Premium Profile	Discount Profile
Market position and catchment	Dominant practice in a growing, affluent catchment area with limited competition within six miles	Small player in a highly saturated urban location with multiple competing practices
Scale and multi-site footprint	Multi-site group (3+ locations) with centralised management, shared back-office, and unified brand	Single-site practice with no expansion capacity and no adjacent premises available
NHS contract security and UDA delivery	Consistently meeting or exceeding UDA targets; no clawback history; strong performer list	Chronic UDA underperformance; imminent clawback risk; difficulty attracting NHS performers
Organic growth engine	Systematic referral network, specialist marketing, strong SEO, and active community engagement	No marketing strategy; reliant entirely on word-of-mouth and passing footfall
Exit readiness	Clean legal structure (limited company or well-structured partnership); prepared data room; NHS change-of-control consent planned	Sole trader structure requiring complex partnership route; unresolved disputes; no preparation

The 2026 EBITDA Multiples Ladder

The ranges below are derived from the NASDAL Goodwill Survey (Tier 1), independent goodwill survey data (Tier 1), published transaction evidence (Tier 1), and DealFlowAgent's own advisory experience (labelled as such). The lower bound of each band represents an unprepared business sold without competitive tension. The upper bound represents a prepared business, professionally represented, in a competed process.

£250K to £500K Defended EBITDA

Attribute	Detail
Multiple Range	4.0x to 6.0x
Who Buys	First-time buyers (33% of all dental sales in published 2025 transaction data), ambitious associates stepping into ownership, and local independent operators seeking a second site
The Process	Heavily reliant on bank financing. Lenders scrutinise the buyer's clinical experience, the practice's cash flow sustainability, and the lease terms. Timelines of 4 to 8 months are typical.
The Discount	Buyers discount heavily for principal dependency. If the exiting owner generates most of the revenue, the buyer faces immediate clinical replacement risk and the EBITDA figure is not defensible without them.
Highest-Value Move	Transitioning clinical hours to associates over 12 to 24 months to prove the practice generates profit independent of the owner's chair time.

£500K to £1M Defended EBITDA

Attribute	Detail
Multiple Range	5.0x to 7.5x
Who Buys	Regional groups, emerging platforms (e.g., DeNovo Dental Partners), and established independent multi-site operators looking for add-on acquisitions
The Process	More structured. Buyers seek "add-on" acquisitions to integrate into existing infrastructure. Diligence focuses heavily on associate contracts, compliance status, and premises condition.
The Discount	Short lease terms (under 10 years) or significant capital expenditure requirements (failing HTM 01-05 compliance, outdated equipment) will be deducted directly from the enterprise value.
Highest-Value Move	Securing long-term associate tie-ins with 6-month notice periods and restrictive covenants, and ensuring the premises lease has at least 10 to 15 years remaining or the freehold is included.

£1M to £2M Defended EBITDA

Attribute	Detail
Multiple Range	7.0x to 9.0x
Who Buys	National corporates (PortmanDentex, Rodericks Dental Partners, mydentist), mid-market private equity platforms, and the larger US DSOs entering the UK market
The Process	Highly professionalised. Corporate development teams run rigorous financial, legal, and clinical diligence. Earn-outs and deferred consideration become standard structuring tools. Deal timelines of 6 to 10 months.
The Discount	Inconsistent NHS contract delivery. A history of UDA clawback signals operational inefficiency and introduces revenue risk that corporates will penalise with a 1.0x to 2.0x reduction (DealFlowAgent estimate).
Highest-Value Move	Demonstrating a strong, growing private plan membership base (recurring revenue) alongside a fully utilised, associate-led clinical team with documented SOPs.

£2M to £3M Defended EBITDA

Attribute	Detail
Multiple Range	8.0x to 10.0x
Who Buys	Top-tier national corporates and private equity firms looking for strong regional hubs with management depth
The Process	Competitive auction processes run by specialist sell-side advisers. Buyers are willing to pay a premium for scale, established management layers, and integration-ready systems.
The Discount	Lack of management depth. If a £2.5M EBITDA group still relies on the founder for daily operational decisions, it is not a true platform and will not command platform pricing.
Highest-Value Move	Institutionalising the management team: having a strong group practice manager and clinical director in place who will remain post-sale, with incentive alignment through equity or bonus structures.

£3M to £5M Defended EBITDA

Attribute	Detail
Multiple Range	9.0x to 11.0x
Who Buys	Private equity sponsors seeking new platform investments, or major international DSOs entering new territories
The Process	Intense scrutiny on the scalability of central systems (finance, HR, compliance, marketing, clinical governance). Buyers are acquiring an infrastructure, not just a collection of clinics.
The Discount	Poor integration of previous acquisitions. If the group operates as disparate clinics rather than a unified brand with centralised SOPs, the multiple drops to the add-on range.
Highest-Value Move	Proving that the central management infrastructure can seamlessly absorb another 5 to 10 practices without breaking, supported by documented integration playbooks.

£5M to £10M Defended EBITDA

Attribute	Detail
Multiple Range	10.0x to 12.0x
Who Buys	Large-cap private equity, global healthcare conglomerates, and international dental groups
The Process	Highly strategic. These assets are rare in the UK market. The process involves deep strategic alignment discussions, often with the founders rolling over significant equity into the new structure.
The Discount	Growth ceiling. Buyers at this level need a clear pathway to double the business within their hold period; a saturated regional footprint or inability to attract further acquisition targets limits the multiple.
Highest-Value Move	Articulating a clear, data-backed buy-and-build strategy with a pipeline of identified acquisition targets and the management capacity to execute it.

£10M+ Defended EBITDA

Attribute	Detail
Multiple Range	11.0x to 14.0x+
Who Buys	Major global buyout funds, sovereign wealth-backed vehicles, and public markets (via IPO or SPAC)
The Process	Complex, multi-jurisdictional M&A processes. Deals are structured to align long-term incentives, often involving sophisticated equity ratchets, management incentive plans, and multi-year earn-outs.
The Discount	Regulatory concentration risk, over-exposure to a single reimbursement model (e.g., 80%+ NHS), or geographic concentration that limits further growth.
Highest-Value Move	Demonstrating exceptional revenue diversification across NHS, private, and plan income, with a highly professionalised, autonomous C-suite that operates independently of any single founder.

Footnote: Businesses generating under £250,000 in adjusted profit are typically valued on a Seller's Discretionary Earnings (SDE) basis rather than an EBITDA multiple, generally attracting 2.0x to 3.5x SDE. Independent goodwill survey data records the average independent buyer multiple at 3.44x, which aligns with this SDE-priced segment. Indicative revenue bands are not provided, as dental practice margins vary significantly based on the principal's clinical contribution and the NHS/private mix.

Calculate your indicative valuation

The Cost of Compliance: Regulatory Economics

Every dental practice in the UK operates inside a dense regulatory perimeter, and the direct and indirect costs of that perimeter feed straight into adjusted EBITDA. Buyers do not treat compliance cost as a footnote; they model it line by line, because a practice with a compliance backlog is a practice with a hidden capital expenditure liability. This section sets out the specific fees, timelines, and buyer-side diligence points for each of the six regulatory regimes that shape dental practice economics, so that owners can see exactly where their numbers will be tested.

CQC registration (Care Quality Commission)

Every dental practice providing regulated activities in England must be registered with the Care Quality Commission. The application fee is a one-off, non-refundable £1,522, and registration typically takes 8 to 16 weeks, longer if compliance issues are identified during the process. Annual fees for 2026-27 are confirmed with no increase on the prior year, and scale with surgery count: £598 for a single-chair practice, £747 for two chairs, £846 for three chairs, £945 for four chairs, and £945 plus £99 per additional chair beyond that. A lapsed or cancelled registration means the practice cannot legally operate, an immediate closure event, and the CQC retains the power to cancel registration for persistent non-compliance. Under the single assessment framework introduced from 2023, inspectors assess five key questions: Safe, Effective, Caring, Responsive, and Well-led, each supported by quality statements. Buyers will pull the last inspection report, confirm there are no conditions attached to the registration, and establish whether the registered manager is remaining post-completion or whether a replacement has already been identified and approved.

GDC registration (General Dental Council)

The General Dental Council sets the Annual Retention Fee that every practising clinician must pay to remain on the register. For 2026, this is £698 per dentist and £108 per dental care professional (hygienists, therapists, and nurses on the DCP register), a 12.4% increase on the 2025 dentist fee of £621. New registrants pay the same £698 registration fee. Without current GDC registration, a dentist cannot legally practise, so if a principal's registration lapses, the practice loses its clinical capability overnight. Because the GDC register is publicly searchable, buyers verify every clinician's registration status individually and check for open fitness-to-practise proceedings, conditions, or suspensions before making an offer.

NHS dental contract economics (GDS/PDS)

The NHS General Dental Services and Personal Dental Services contracts are priced in Units of Dental Activity, with national average UDA values running at roughly £28 to £32 per unit in 2025/26. Contract value is calculated as the annual UDA target multiplied by the agreed UDA rate, and it is this figure that constitutes the guaranteed NHS income line in a practice's accounts. If a practice fails to hit its delivery threshold, typically 96% of target, NHS England claws back funding proportionally, and a clawback history is one of the fastest ways to depress a valuation, as covered in What Kills the Multiple above. Contract reform implementing from April 2026 changes the underlying quality and payment framework, discussed in more detail in Demand Drivers and Regulatory Calendar. Transferring the contract on a sale requires NHS England (through the relevant Integrated Care Board) approval, a process that typically takes 3 to 6 months and is not guaranteed, via either the partnership route or a share sale where the contract-holding company changes ownership, both of which are set out in full in The NHS Contract: Transfer Mechanics and Their Impact on Value. Buyers will ask what the UDA delivery rate has been against target, whether any clawback has occurred in the last three years, whether the contract sits with an individual or a limited company, and what the local commissioning team's track record is on approving transfers.

IRR17 (Ionising Radiation Regulations 2017)

Every practice operating X-ray equipment falls under the Ionising Radiation Regulations 2017, which require appointment of a Radiation Protection Adviser and a Radiation Protection Supervisor, documented local rules, a quality assurance programme, and dose monitoring. A Radiation Protection Adviser typically costs £500 to £1,500 per year to retain, and each X-ray unit requires annual testing costing £200 to £500. Non-compliance exposes the practice to HSE enforcement action, up to and including a Prohibition Notice that takes the X-ray equipment out of service, an outcome that stops clinical activity in its tracks. Buyer diligence on this point is mechanical: confirm the Radiation Protection Adviser appointment is current, confirm local rules are documented, and confirm every X-ray unit has a current testing certificate.

HTM 01-05 (decontamination standards)

Health Technical Memorandum 01-05 governs instrument decontamination and sterilisation in dental settings, requiring validated washer-disinfectors and autoclaves with daily, weekly, and quarterly testing regimes, all supported by documented procedures. A compliant decontamination suite costs £15,000 to £40,000 to fit out, and decontamination failure is one of the most common reasons a practice receives a "Requires Improvement" CQC rating. Buyers ask, specifically, whether the decontamination suite is HTM 01-05 compliant, when the equipment was last validated, and whether a documented decontamination log exists, because a capital backlog on this point is deducted from enterprise value pound for pound.

Indemnity insurance

Mandatory since the 2015 amendment to the Dentists Act, indemnity cover for every practising dentist costs £5,000 to £15,000 per year depending on scope of practice, rising for clinicians undertaking implants, sedation, or orthodontics. Cover is provided by the Dental Defence Union, the Medical Defence Union, or Dental Protection Ltd. Without current indemnity, a dentist cannot legally practise, and a poor claims history both raises the premium and signals clinical risk to a prospective buyer. Diligence on this point routinely requests the claims history for every clinician and confirmation of any open claims or pending GDC or NHS complaints.

Scotland, Wales, and Northern Ireland variations

The devolved nations operate materially different NHS dental contract frameworks from the English GDS system. Scotland's contract is administered by NHS Education for Scotland under the Statement of Dental Remuneration, a different unit of measurement to the English UDA. Wales moved ahead of England on contract reform, implementing a new framework from 2022 and refreshing it again from April 2026. Northern Ireland's legacy Health and Social Care Board structure sits on a separate contract basis again. Because transfer processes and contract economics differ by nation, owners outside England should establish which framework applies to their practice early in preparation, and take specialist legal advice before assuming the English transfer mechanics described in this guide apply directly.

Regime	Annual cost driver	Key buyer diligence question
CQC registration	£598-£945+ per year by chair count, plus £1,522 one-off application fee	Is the registration clean, and who holds the registered manager role post-completion?
GDC registration	£698 per dentist, £108 per DCP (2026 Annual Retention Fee)	Is every clinician's registration current with no open fitness-to-practise cases?
NHS GDS/PDS contract	UDA target x UDA rate (~£28-£32 per UDA, 2025/26)	What is the delivery rate against target, and has clawback occurred in the last three years?
IRR17	£500-£1,500/year RPA fee, plus £200-£500 per X-ray unit tested	Is the RPA appointment current and are testing certificates in date?
HTM 01-05	£15,000-£40,000 decontamination suite fit-out	Is the suite compliant and validated, with a documented testing log?
Indemnity insurance	£5,000-£15,000 per dentist per year	Is there a clean claims history across all clinicians?

For owners preparing a practice for sale, this regulatory cost base is not a reason for concern in itself; it is a baseline that every credible buyer expects to see fully documented. The value destruction happens when compliance gaps surface for the first time during diligence rather than being disclosed upfront in a well-organised data room, a theme explored further in The Diligence Question Bank below and in DealFlowAgent's broader exit planning guide.

How These Businesses Are Actually Valued

The dental sector is unique in its valuation conventions. While the broader M&A market speaks exclusively in EBITDA multiples, the UK dental market still heavily references goodwill as a percentage of gross fee income. This creates confusion for owners who encounter both metrics and cannot reconcile them. This section explains both methodologies and demonstrates how they relate to one another.

The Goodwill Percentage Convention

The NASDAL Goodwill Survey is the longest-running dataset in UK dental M&A, published quarterly since 2008. It reports the price paid for dental practices as a percentage of the practice's annual gross fee income. For the quarter ending 31 October 2025, NASDAL reported overall goodwill at 119% of gross fees. Mixed practices commanded a premium at 144%, while purely NHS practices dropped to 111% and private practices sat at 100%.

Independent goodwill survey data provides a complementary dataset. It reports the average completed transaction price at £1,383,637 (the highest in a decade, representing a 7.5% increase on the prior year), with group buyers paying an average of £2,500,709 and independent buyers paying £886,562.

The EBITDA Multiple Convention

Corporate acquirers and private equity firms do not buy revenue; they buy cash flow. They underwrite deals based on Adjusted EBITDA, which is the practice's profit after normalising for the principal's clinical contribution, personal expenses, and one-off items. Independent goodwill survey data records the average group buyer multiple at 7.15x EBITDA, with Tier 2 buyers (groups of 20+ practices) paying up to 7.78x.

Reconciling the Two: The Critical Arithmetic

The relationship between goodwill percentage and EBITDA multiple is determined by the practice's adjusted EBITDA margin. A practice with a 30% adjusted margin selling at 120% of gross fees is achieving a 4.0x EBITDA multiple (120% divided by 30%). A practice with a 20% margin selling at the same 120% is achieving a 6.0x multiple (120% divided by 20%). This reconciliation is the most useful analytical tool on this page, because it allows an owner to translate between the two conventions at their own margin level.

Adjusted EBITDA Margin	Goodwill at 100% of Fees	Goodwill at 120% of Fees	Goodwill at 150% of Fees
20%	5.0x EBITDA	6.0x EBITDA	7.5x EBITDA
25%	4.0x EBITDA	4.8x EBITDA	6.0x EBITDA
30%	3.3x EBITDA	4.0x EBITDA	5.0x EBITDA
35%	2.9x EBITDA	3.4x EBITDA	4.3x EBITDA
40%	2.5x EBITDA	3.0x EBITDA	3.8x EBITDA

The Principal-Hours Normalisation

The single largest adjustment in a dental practice valuation is normalising the principal's clinical hours. If a principal generates £400,000 in gross fees and takes it all as profit, that £400,000 is not EBITDA. A buyer must replace that clinical output with an associate at market rates. If the prevailing associate split is 45%, the buyer incurs £180,000 in replacement costs, reducing the true EBITDA by that amount. DealFlowAgent data indicates that associate-led EBITDA margins typically range from 25% to 40%, depending on the private/NHS mix and operational efficiency.

This normalisation is why the NASDAL goodwill percentage and the EBITDA multiple can appear to tell different stories. A principal-dependent practice may sell at a high goodwill percentage (because the gross fees are large relative to the price), but a low EBITDA multiple (because the adjusted profit after principal replacement is small).

Recurring Revenue: The Plan Premium

In dentistry, recurring revenue takes the form of capitation plans (e.g., Denplan, Practice Plan, DPAS). Buyers place a significant premium on this income because it provides predictable monthly cash flow, reduces reliance on volatile high-ticket cosmetic treatments, and heavily drives patient retention. A practice with 40% of its revenue derived from stable plan memberships will consistently command a higher multiple than a purely fee-per-item practice with identical EBITDA, because the earnings quality is demonstrably superior.

The NHS Contract: Transfer Mechanics and Their Impact on Value

This section addresses the single most common source of deal delay, complexity, and value destruction in UK dental M&A. An NHS General Dental Services (GDS) contract cannot be sold or assigned outright. It is a personal contract between the contractor (the practice owner or partnership) and the NHS commissioner (the Integrated Care Board, formerly the Local Area Team). Understanding the transfer mechanics is essential for any owner considering a sale.

Route 1: The Partnership Route

The traditional method for transferring an NHS contract from a sole practitioner involves the following steps. First, the seller incorporates a partnership with the buyer (or the buyer's nominee). Second, the partnership applies to the commissioner to be added to the contract. Third, after a period of joint operation (typically 3 to 6 months), the original partner retires from the partnership, leaving the buyer as the sole contractor. This route preserves the contract without requiring a new application, but it introduces significant timeline risk. If the commissioner is slow to process the application, or if the buyer's clinical credentials are questioned, the deal can stall for months.

Route 2: The Share Sale

Where the practice is already incorporated (i.e., the NHS contract is held by a limited company), a share sale is the cleaner route. The buyer acquires the shares of the company, and the contract remains within the same legal entity. However, this requires change-of-control consent from the commissioner, which is not automatic. The commissioner will assess the new owners' suitability, clinical governance arrangements, and financial standing. This route is faster than the partnership route but carries the risk that consent is withheld or conditional.

The Valuation Impact

Practices that have not prepared for contract transfer face a direct valuation penalty. A sole-trader structure requiring the partnership route adds 3 to 6 months to the deal timeline, increases legal costs, and introduces the risk of the buyer walking away during the extended transition period. Corporates will either discount the price to reflect this risk or, increasingly, simply decline to make an offer on poorly structured practices. The single most valuable preparatory step for any NHS practice owner planning a sale within 24 months is to incorporate the practice and hold the contract within a limited company, removing the partnership route requirement entirely.

Scotland, Wales, and Northern Ireland

The NHS dental contract regimes in Scotland, Wales, and Northern Ireland differ materially from the English GDS system described above. Wales implemented a new NHS dental contract from 1 April 2026, the first major reform in over 20 years. Scotland operates under a different commissioning structure through NHS boards. This guide's contract transfer analysis applies specifically to England. Owners in the devolved nations should seek specialist legal advice on their specific regime.

What Kills the Multiple

Corporate development directors look for reasons to say no. In the dental sector, these six issues reliably destroy enterprise value during diligence. Each is written from the buyer's perspective, because that is the voice that determines the price.

"The principal is the practice." If the exiting owner generates 70% of the clinical revenue and holds all the key patient relationships, the business has no transferable goodwill. We are buying a job, not an asset, and the multiple will reflect that extreme key person risk. We will apply a replacement cost that reduces the EBITDA to a fraction of what the seller's accountant presented, and we will apply a discount multiple to that reduced figure.
"The NHS contract is chronically underperforming." A history of missing UDA targets and suffering clawbacks tells us two things: the practice cannot attract or retain associates willing to deliver NHS care, and the revenue base is insecure. Clawback is not a one-off event; it is a structural indicator of operational failure. We will discount the valuation heavily, and in some cases we will simply walk away rather than inherit the problem.
"The associates are on a hair-trigger." If the associates have no well-drafted contracts, no restrictive covenants, or are threatening to leave if the practice is sold, the revenue is entirely unprotected. Patient loyalty in dentistry follows the clinician, not the brand. If the associates leave, the patients leave with them. We will not pay a premium multiple for a flight-risk clinical team.
"The premises are a liability." A short lease (under 10 years) with no right of renewal, or a freehold that requires massive capital expenditure to meet HTM 01-05 decontamination standards, represents immediate risk and cost. We will deduct that capex directly from the purchase price, pound for pound. A practice requiring £200,000 of equipment upgrades is worth £200,000 less than an identical practice that is fully compliant.
"The NHS contract transfer is a mess." Because a GDS contract cannot be sold outright, a poorly structured sole-trader practice requires a complex partnership route or incorporation process to transfer the contract. If the seller has not prepared this, the deal timeline extends by months, deal fatigue sets in, and offers drop. We have seen deals collapse entirely because the seller did not understand this mechanic until month six of the process.
"The numbers are fiction." Presenting 'adjusted EBITDA' that adds back legitimate business expenses, or failing to properly deduct the market-rate cost of the principal's clinical hours, destroys trust immediately. If the seller's broker does not understand dental normalisation, we assume the rest of the data room is equally flawed. We will either walk away or recut the numbers ourselves and offer on our figure, which will be materially lower.

Worked Examples: Goodwill vs EBITDA

To illustrate how the market convention (goodwill percentage) reconciles with the corporate underwriting standard (EBITDA multiple), consider two illustrative practices. Both generate £1,000,000 in gross fee income, but their operational structures yield vastly different valuations.

Practice A: The Discount Profile (Principal-Dependent, Mixed NHS/Private)

Line Item	Amount
Gross Fee Income	£1,000,000
Principal's Clinical Contribution	£600,000 (4 days per week)
Associate and Hygiene Contribution	£400,000
Reported Profit (before principal replacement)	£450,000
Less: Associate Replacement Cost (45% of £600,000)	(£270,000)
True Adjusted EBITDA	£180,000 (18% margin)
Multiple Applied (unprepared, single buyer)	5.0x
Enterprise Value	£900,000
Goodwill Equivalent	90% of gross fees

Practice B: The Premium Profile (Associate-Led, Strong Plan Income)

Line Item	Amount
Gross Fee Income	£1,000,000
Principal's Clinical Contribution	£100,000 (1 day per week)
Associate and Hygiene Contribution	£900,000
Reported Profit (before principal replacement)	£350,000
Less: Associate Replacement Cost (45% of £100,000)	(£45,000)
True Adjusted EBITDA	£305,000 (30.5% margin)
Multiple Applied (prepared, competed process)	7.5x
Enterprise Value	£2,287,500
Goodwill Equivalent	229% of gross fees

These examples are illustrative constructions to demonstrate the mathematics of principal replacement. They are not market data.

The difference is stark: the same gross fee income produces enterprise values ranging from £900,000 to £2,287,500, a gap of £1.4 million driven entirely by operational structure and process quality. Practice B commands a higher multiple (7.5x vs 5.0x) applied to a higher EBITDA base (£305,000 vs £180,000), creating a compounding effect that rewards preparation.

2025 and 2026 Transactions: United Kingdom

Individual deal values in the dental sector are almost never disclosed. Unlike building services or fire safety M&A, where trade press occasionally reports consideration, dental practice sales are private transactions between a corporate and an owner-operator. Neither party publishes the price. The table below tracks confirmed corporate and group acquisition activity with consideration marked undisclosed where it is undisclosed. This is the honest position, and it is more useful than a fabricated figure.

Date	Target	Acquirer	Type	Consideration	Details	Source
Nov 2025	Central England Specialist Referral Centre, Solihull	DeNovo Dental Partners	PE bolt-on	Undisclosed	Five-surgery specialist/referral centre	Published market data
Nov 2025	Kirkliston Dental Surgery, Edinburgh	Vineeth Balachandran	Independent group	Undisclosed	Four-surgery mixed-income, ~7,750 patients	Published market data
Jul 2025	mydentist (500+ practices)	Bridgepoint	PE platform	Circa £800 million	UK's largest dental provider; 3,500+ professionals, 2,500+ surgeries	Bridgepoint
Jul 2025	Clifton Dental, Cardiff	Imtiaz Khan	Independent	Undisclosed	Six-surgery, mixed-income, revenue close to £1.6m	Published market data
Jun 2025	The Park Clinic	Mosaic Dental Group	Group bolt-on	Undisclosed	Seven-surgery private dental practice and specialist referral centre	Published market data
Apr 2025	Priestgate Business Centre, Cambridgeshire	PortmanDentex	Corporate	Undisclosed	Five-surgery, private clinic	Published market data
Apr 2025	Duncan Smith Dental Practice, East Lothian	Scottish Dental Care Group	Group bolt-on	Undisclosed	Five-surgery, mixed-income	Published market data
Feb 2025	The Priestgate Clinic, Peterborough	PortmanDentex	Corporate	Undisclosed	Five-surgery, private practice	Published market data
Feb 2025	Six practices (South of England)	DeNovo Dental Partners	PE platform launch	Undisclosed	Shared ownership model; principals retain autonomy	Published market data

What this table says when read together. The UK market is highly active but heavily bifurcated. While mega-deals like Bridgepoint's circa £800 million acquisition of mydentist dominate the headlines, the day-to-day market is driven by independent operators and emerging regional groups acquiring high-quality, multi-surgery clinics. Published market data records 165 practices advised on, agreed, or sold in Q1 2026 alone, with a combined value of £167 million. Corporate buyers represent only 7% of completed transactions, but approximately 20% of the live pipeline is expected to complete into corporate ownership. The emergence of DeNovo's shared-ownership model represents a new structural option for principals who want liquidity without full exit.

Are you actively acquiring dental practices in the UK or US? Register your investment criteria with DealFlowAgent to receive off-market opportunities matching your mandate.

Book a confidential valuation call with DealFlowAgent

2025 and 2026 Transactions: United States

The US DSO market operates at a staggering scale, but like the UK, individual practice transaction values are strictly confidential. In the June 2026 Group Dentistry Now acquisition roundup, every operating-company acquisition was recorded as undisclosed. That is the norm, not an outlier.

Date	Target	Acquirer	Type	Consideration	Source
Mar 2026	4 partnerships + 1 de novo (FL, GA, TX, MN, OK)	MB2 Dental	DSO partnership	Undisclosed	Group Dentistry Now
Mar 2026	5 de novos + 2 affiliations	Heartland Dental	DSO	Undisclosed	Group Dentistry Now
Mar 2026	2 partnerships (AZ, WA)	Imagen Dental Partners	DSO partnership	Undisclosed	Group Dentistry Now
Mar 2026	North Florida Oral & Facial Surgery (5 locations)	Beacon Oral Specialists	Specialty DSO	Undisclosed	Group Dentistry Now
Mar 2026	4 partnerships + 1 de novo	SALT Dental Partners	DSO	Undisclosed	Group Dentistry Now
Mar 2026	2 partnerships (PA, ID)	Specialized Dental Partners	DSO	Undisclosed	Group Dentistry Now
Mar 2026	2 partnerships (TN)	Innovate 32	DSO	Undisclosed	Group Dentistry Now
Mar 2026	2 partnerships (GA, IL)	Smile Partners USA	DSO	Undisclosed	Group Dentistry Now

What this table says when read together. The US market is characterised by relentless, programmatic M&A driven by private equity-backed DSOs. Platforms like MB2 and Heartland execute multiple partnerships monthly. The emergence of specialty DSOs (like Beacon Oral Specialists, now supporting 130+ oral surgeons across 106 locations) indicates a maturing market where buyers are willing to pay premiums for high-margin, specialised clinical models. The "partnership" terminology used by MB2 and Imagen reflects the joint venture structure common in US dental M&A, where the selling dentist retains equity in the local entity and participates in the platform's eventual recapitalisation.

The Buyer Universe: Who is Acquiring in 2026

United Kingdom

Acquirer	Type	Scale	2025-2026 Activity	Source
PortmanDentex	Corporate (PE-backed)	370+ practices	Active: Priestgate acquisitions (Feb/Apr 2025)	Published market data
mydentist	Corporate (Bridgepoint)	500+ practices	Bridgepoint acquisition Jul 2025; new Cardiff practice Mar 2026	Bridgepoint
Bupa Dental Care	Corporate (Bupa Group)	~389 practices	Portfolio optimisation; closed/sold 85 practices in 2023 due to NHS workforce issues	Published market data
Rodericks Dental Partners	Corporate (CapVest)	~226 practices	Continuing scale build post-CBPE exit	Published market data
Scottish Dental Care Group	Regional group (BGF-backed)	30+ practices	Duncan Smith acquisition Apr 2025; Musselburgh Apr 2025	Scottish Financial News
DeNovo Dental Partners	Emerging platform	6+ practices	Launched Feb 2025; Central England Nov 2025	Published market data
Mosaic Dental Group	Regional group	Growing	The Park Clinic acquisition Jun 2025	Published market data

United States DSOs

Acquirer	Type	Scale	2025-2026 Activity	Source
Heartland Dental	National DSO	1,900+ offices	5 de novos + 2 affiliations (Mar 2026 alone)	Group Dentistry Now
PDS Health	National DSO (dentist-led)	1,000+ offices, 24 states	2 de novos (VA, CA) Mar 2026	Becker's Dental
MB2 Dental	National DSO (JV model)	Hundreds of partners	4 partnerships + 1 de novo Mar 2026	Group Dentistry Now
Dental Care Alliance	National DSO	~400 practices, 24 states	Active acquirer	Becker's Dental
Imagen Dental Partners	Regional DSO (dentist-led)	Growing rapidly	2 partnerships (AZ, WA) Mar 2026	Group Dentistry Now
SALT Dental Partners	Regional DSO	Growing	4 partnerships + 1 de novo Mar 2026	Group Dentistry Now

Note: The corporate market consolidates rapidly. Inclusion on this list indicates verified recent activity, but acquisition appetite fluctuates based on funding cycles, integration capacity, and regulatory developments. A page that lists a dormant acquirer as active is worse than a shorter list.

Match with active buyers for your practice

Demand Drivers and Regulatory Calendar

The regulatory environment dictates practice operations, deal structures, and ultimately valuations. The UK dental market is experiencing a period of significant regulatory change, with three major developments occurring within a 12-month window.

The CMA Private Dentistry Market Study (March 2026 to March 2027)

The Competition and Markets Authority launched a 12-month market study into private dentistry on 5 March 2026, examining an £8.4 billion market. The BDA reported that interim findings confirm the market is "competitive and well-functioning," with an 8% real-terms reduction in private fees (practices absorbing cost increases rather than passing them to patients). Published market data confirms that the study has not dampened buyer appetite: offer volumes in H1 2026 are in line with H1 2025, while aggregate offer value is up approximately 43%. However, deal execution timelines have extended from 7.6 months to 8.8 months as buyers demand greater transparency and tighter warranties.

NHS UDA Reform (April 2026)

NHS England implemented significant contract changes from 1 April 2026, the first material reform to the UDA system since its introduction in 2006. Key changes include a mandate that 8.2% of contract value be directed to unscheduled care (11 Courses of Treatment per £10,000 of contract value), a new £75 payment structure for urgent access, rebanding of fissure sealants from Band 1 to Band 2 (increasing from 1 UDA to 3-5 UDAs), and an optional quality improvement programme worth £3,400 per practice per year. These changes alter the margin structure of NHS delivery and create both opportunities and risks for practices depending on their current service mix.

GDC Scope of Practice (November 2025)

The General Dental Council's revised Scope of Practice guidance, effective 1 November 2025, moved from fixed task lists to competency-based role descriptions. Dental hygienists and therapists can now carry out a wider range of treatments if trained, competent, and indemnified. This fundamentally improves practice skill-mix efficiency and allows practices to deliver more care through lower-cost clinicians, directly improving EBITDA margins for practices that adapt their clinical model accordingly.

Additional UK Regulatory Factors

Regulation	Impact on Value
CQC Registration	Registration status and Registered Manager continuity are completion mechanics. The CQC does not rate dental practices.
Performer Lists	Individual clinician eligibility to provide NHS care; a diligence item for associate retention
GDC Indemnity Requirements	Continuity of cover and run-off on a sale; a cost that must be factored into completion accounts
IRR 2017 / IR(ME)R	Radiation regulation; non-compliance carries capital consequences for equipment replacement
HTM 01-05	Decontamination standards; compliance carries a capital expenditure requirement that buyers deduct where a backlog exists

United States Regulatory Factors

The US regulatory landscape is fundamentally different. There is no federal dental licensing regime; each of the 50 states operates its own dental board with distinct rules on scope of practice, supervision requirements, and corporate ownership. The corporate practice of dentistry doctrine, which in most states prevents non-dentist ownership of a clinical practice, is the structural fact that explains why US dental M&A operates through the DSO model. A DSO cannot own the clinical entity (the Professional Corporation); it provides management services under an MSA. This structure has specific implications for deal mechanics, tax treatment, and post-acquisition governance that vary by state.

Deal Structure: How the Consideration is Paid

Corporate buyers rarely write a single cheque for 100% of the enterprise value on completion day. Risk is shared between buyer and seller through structured consideration.

United Kingdom vs United States Comparison

Element	UK Market Norms	US Market Norms	Implication for Sellers
Upfront Cash	70% to 80% of enterprise value	60% to 80% of enterprise value	Sellers must be prepared to leave significant value tied up in the business post-completion
Earn-Outs / Deferred	20% to 30% tied to EBITDA or UDA delivery targets over 1 to 3 years	Common, often tied to associate retention and revenue growth over 2 to 3 years	Missed targets post-sale mean the headline multiple is never fully realised
Equity Rollover	Less common for single clinics; increasingly seen in group sales to PE platforms	Highly common (Joint Venture models like MB2, Imagen); sellers retain 20% to 40% equity	US sellers often get a "second bite of the apple" when the DSO recapitalises at a higher multiple
Working Capital	Cash-free, debt-free with a normalised working capital target; NHS debtors and plan prepayments require careful treatment	Cash-free, debt-free; patient prepayments and insurance receivables normalised	Sellers must leave enough cash in the business to fund day-to-day operations; the completion accounts adjustment can surprise unprepared sellers
Restrictive Covenants	Typically 2 to 3 years, 3 to 5 mile radius	Varies by state; typically 2 years, 10 to 25 mile radius	Sellers cannot compete or solicit patients within the restricted area

Three Implications for Sellers

First, the headline multiple is not the cash-in-hand figure. A 7.0x multiple with a 25% earn-out means the guaranteed day-one payment is 5.25x, and the remaining 1.75x depends on hitting targets that the seller no longer controls. Second, equity rollover can be highly valuable if the platform executes its buy-and-build strategy successfully, but it is illiquid and carries execution risk. Third, the working capital adjustment is the most common source of post-completion disputes in dental M&A; sellers should model it carefully with their accountant before signing heads of terms.

Public Company Multiples

Public company multiples reflect global investor sentiment, liquidity premiums, and massive scale. There is no direct read-across from these figures to the valuation of a private, lower mid-market dental practice. Data retrieved August 2026.

Pure-play listed dental operators are exceptionally rare, as the sector is dominated by private equity. The major UK corporates (mydentist, PortmanDentex, Rodericks) are all privately held. In the US, no major DSO is publicly listed. The closest public comparables are dental supply and distribution companies, which operate fundamentally different business models.

Company	Ticker	Business	Relevance to Clinical Practices
Henry Schein	HSIC (NASDAQ)	Dental supply distribution	Reflects supply chain economics, not clinical service delivery
Patterson Companies	PDCO (NASDAQ)	Dental supply distribution	Same as above; no read-across to practice multiples

The true valuation benchmark for clinical dental practices remains the private market data published by NASDAL and independent sector surveys, supplemented by the transactional experience of specialist advisers.

For owners 12 to 36 months from a sale event, we build a detailed valuation and business optimisation report that typically identifies six to seven figures of additional enterprise value. Available standalone, or included as part of our sell-side advisory engagement for businesses planning a sale within 12 months. Book a confidential call to discuss your practice.

The Diligence Question Bank

Once heads of terms are agreed, a buyer's financial, legal, and clinical advisers will work through a structured question set before releasing funds. The 25 questions below are drawn from real corporate and private equity diligence processes in the sector, grouped into the five areas that determine both the multiple and the shape of the deal. Owners who can answer every question below with a documented, ready-to-share answer will move through diligence materially faster, and materially reduce the risk of a late price chip.

Financial (questions 1-5)

Provide a month-by-month revenue breakdown for the last 36 months, split by NHS contract income, private fee income, hygienist and therapist revenue, specialist referral income (implants, orthodontics, endodontics), and any capitation plan income (Denplan, Practice Plan, or equivalent).
What is the NHS UDA target, actual delivery rate, and UDA value for the last three contract years? Has there been any clawback, and what is the expected position under the 2026/27 reformed contract?
What is the gross margin by revenue stream, specifically associate costs as a percentage of fee income, lab fees, materials, and hygienist costs?
How many active patients are registered? What is the patient-to-chair ratio, the new patient acquisition rate per month, and the patient attrition rate?
What is the practice plan membership across Denplan, Practice Plan, or in-house schemes: number of members, average monthly fee, retention rate, and what is included in the plan?

Clinical and operational (questions 6-10)

List every clinician by name, GDC number, employment status (principal, associate, or employed), days worked per week, and scope of practice, including implants, orthodontics, endodontics, sedation, and facial aesthetics.
What is the associate retention rate? List any associates who have left in the last three years and the stated reason, and confirm whether restrictive covenants exist in associate agreements.
What dental practice management software is used (for example Dentally, Software of Excellence, Exact, or iSmile), and can full patient records, treatment plans, and financial data be exported cleanly?
What is the chair utilisation rate, measured as booked hours over available hours, and what is the did-not-attend rate, benchmarked against an industry target of 85%+ utilisation and a sub-5% DNA rate?
What specialist equipment is in place, including CBCT scanners, digital impression scanners such as iTero or Trios, lasers, sedation equipment, or microscopes, and what is its age and condition?

Regulatory (questions 11-15)

Provide the last CQC inspection report and current rating. Are there any conditions on registration, warning notices, or outstanding requirement notices?
Who is the registered manager with CQC? If it is the selling principal, who will replace them, given the CQC requires a registered manager to be in place at all times?
Provide GDC registration confirmation for every clinician. Are there any open fitness-to-practise cases, conditions, or undertakings against any registrant?
Provide IRR17 compliance evidence: the Radiation Protection Adviser appointment letter, local rules, X-ray equipment testing certificates, and dose records.
Provide HTM 01-05 decontamination compliance evidence: equipment validation certificates, daily, weekly, and quarterly testing logs, and documented procedures.

NHS contract (questions 16-20)

Is the NHS contract held by an individual or a limited company? If held individually, what transfer route is proposed, and has the relevant commissioning body been consulted?
What is the contract activity breakdown by treatment band (Band 1, 2, and 3), and what is the mix of UDAs delivered by the principal versus associates?
Has the practice ever received a breach notice, remedial notice, or contract performance notice from the commissioner? Provide details and confirm resolution.
Where applicable, what is the orthodontic contract position, including the UOA target, delivery rate, and current waiting list?
Where the 2026/27 contract reforms apply, what is the expected revenue impact, and has the practice modelled the new quality and payment framework?

Legal and property (questions 21-25)

Provide the practice lease: term, rent, rent review mechanism, break clauses, assignment provisions, and any restrictions on use or alterations.
If freehold, provide title documents, details of any charges, and a recent valuation, and confirm whether the property is included in the sale or retained by the seller.
Provide all associate agreements, including fee split, notice periods, restrictive covenants (radius and duration), and any goodwill provisions.
Provide details of all equipment leases and hire-purchase agreements: what transfers with the practice, and what is the outstanding balance?
Are there any ongoing patient complaints, GDC referrals, NHS ombudsman cases, or clinical negligence litigation?

A well-organised data room that answers all 25 questions before they are asked signals a professionalised seller and materially shortens the deal timeline discussed in Deal Structure: How the Consideration is Paid. DealFlowAgent builds this data room as a core part of preparing owners for a confidential sale process.

The 12-Month Preparation Timeline

Preparing a dental practice for sale is a sequencing exercise. The actions below are grouped into five phases across a 12-month runway, moving from regulatory foundations through revenue quality, operational independence, financial preparation, and finally market readiness. Owners with a longer runway should still work through the phases in this order, because each phase depends on the groundwork laid in the one before it.

Months 12-10: regulatory foundation

Start by checking the current CQC rating. A practice rated below "Good" will sell at a significant discount or may be unsaleable until deficiencies are addressed, so any issues need attention immediately, not in month two. Verify that every clinician's GDC registration is current and free of fitness-to-practise concerns. Ensure IRR17 compliance is fully documented, covering the Radiation Protection Adviser appointment, local rules, and equipment testing. Audit HTM 01-05 decontamination compliance and replace any non-compliant equipment now, since washer-disinfectors carry an 8 to 12 week lead time. If the NHS contract is held personally rather than through a limited company, take legal advice immediately on the optimal transfer structure: converting to a company can take 6 to 12 months and requires commissioner approval, as set out in The NHS Contract: Transfer Mechanics and Their Impact on Value. Finally, review associate agreements to confirm restrictive covenants are enforceable, with a reasonable radius and duration.

Months 9-7: revenue quality

Grow private revenue and reduce NHS dependency where possible; mixed practices with a 40% to 60% private split command higher multiples than practices at 90%+ NHS. Build plan membership, targeting 500 or more patients on Denplan, Practice Plan, or an equivalent scheme, because this recurring revenue does not depend on the NHS contract cycle. Reduce principal dependency: if the principal generates 50% or more of clinical revenue, begin transitioning patients to associates now, since buyers discount heavily for key-person risk, as covered in What Kills the Multiple. Recruit or retain a strong associate team, because buyers will discount sharply if key associates are likely to leave post-sale. Maximise chair utilisation by filling empty sessions and reducing the DNA rate, and consider investing in specialist capability such as implants, Invisalign orthodontics, or facial aesthetics, all of which add revenue and attract premium buyers.

Months 6-5: operational independence

Appoint a practice manager, if one is not already in place, capable of running day-to-day operations without the principal. Ensure the CQC registered manager is someone other than the selling principal, or have a clear transition plan in place. Implement or upgrade practice management software so that at least six months of clean data exists showing utilisation, revenue per clinician, and patient metrics. Document all clinical protocols, staff training records, and compliance procedures. Reduce the owner's clinical sessions to a maximum of two to three days per week, to demonstrate the practice runs without the principal present every day.

Months 4-3: financial preparation

Engage a specialist dental accountant to prepare normalised management accounts, and calculate defended EBITDA by stripping out above-market drawings, personal expenses, and one-off costs. Model the impact of principal exit explicitly: what happens to revenue when the principal stops treating patients is the single biggest valuation risk in dental M&A, as demonstrated in the worked examples above. Prepare a full patient analysis covering active patient numbers, new patient rate, attrition rate, average revenue per patient, and plan membership. Finally, obtain a professional valuation from a specialist dental broker or M&A adviser, ideally using DealFlowAgent's free valuation tool as a starting benchmark.

Months 2-1: market readiness

Prepare a confidential information memorandum or engage a specialist dental broker. Brief associates on the sale in a controlled way, since they will find out eventually, and it is better to manage the message and offer retention incentives than to let rumour do the talking. Ensure all CQC, GDC, IRR17, and HTM 01-05 compliance is documented and current, and assemble the full data room: three years of accounts, NHS contract documentation, associate agreements, the lease, equipment schedule, patient numbers, CQC reports, insurance, staff contracts, and a business plan or forecast. Where an NHS contract transfer is required, begin informal discussions with the relevant commissioning body about process and timeline now, rather than after an offer is accepted. Owners at this stage should also review DealFlowAgent's buyer-match service to understand which acquirers are actively looking for a practice with their specific profile.

Phase	Timing	Primary focus
Regulatory foundation	Months 12-10	CQC rating, GDC registration, IRR17, HTM 01-05, contract structure
Revenue quality	Months 9-7	Private/NHS mix, plan membership, principal dependency, chair utilisation
Operational independence	Months 6-5	Practice manager, registered manager, clean data, reduced owner hours
Financial preparation	Months 4-3	Normalised accounts, defended EBITDA, patient analysis, professional valuation
Market readiness	Months 2-1	CIM, broker engagement, associate briefing, data room, commissioner discussions

For owners further than 12 months from a transaction, DealFlowAgent's exit planning guide sets out the same sequencing across a longer runway, and the full library of valuation guides covers adjacent healthcare sectors including care homes for owners considering diversification.

FAQ

What is the average EBITDA multiple for a dental practice in 2026?

For a prepared, associate-led practice generating £500K to £1M in defended EBITDA, the multiple typically ranges from 5.0x to 7.5x. Larger groups generating £1M to £2M command 7.0x to 9.0x. Independent goodwill survey data records the average group buyer multiple at 7.15x.

How does goodwill percentage compare to EBITDA multiples?

Goodwill is calculated as a percentage of gross fee income (e.g., 119% overall in Q1 2026 per NASDAL). EBITDA multiples apply to the adjusted profit. The relationship depends on the practice's adjusted margin: a practice with a 25% margin selling at 120% of fees achieves a 4.8x EBITDA multiple. A practice with a 20% margin at the same goodwill percentage achieves 6.0x.

Does a CQC rating affect my dental practice valuation?

No. The CQC does not issue ratings to dental practices. Unlike hospitals and care homes, dental practices are registered but not rated. What matters for valuation purposes is a clean registration status and a smooth transition of the Registered Manager, which is a completion mechanic rather than a value driver.

How do my clinical hours affect the valuation?

Buyers will deduct the cost of replacing your clinical hours (typically at a 45% to 50% associate split) from your reported profit to calculate the true Adjusted EBITDA. A principal working 4 clinical days per week and generating £500,000 in fees creates a replacement cost of £225,000 to £250,000. This is the single largest normalisation adjustment in dental valuation.

Can I sell my NHS dental contract?

No. An NHS General Dental Services (GDS) contract cannot be sold or assigned outright. It must be transferred either by incorporating the practice and executing a share sale (requiring change-of-control consent from the Integrated Care Board) or via the partnership route, where the buyer is added to the contract before the seller retires. Both routes have specific timelines and risks.

What multiple do US DSOs pay for dental practices?

US DSO multiples vary significantly by scale. Single-location practices typically attract 5.0x to 7.5x as add-on acquisitions. Multi-location groups with $1M to $3M EBITDA command 7.0x to 9.0x. Platform-grade groups with $5M+ EBITDA and full management infrastructure can achieve 10.0x to 12.0x or higher.

How long does it take to sell a dental practice?

Published transaction data indicates the average time from offer accepted to completion is now trending toward 8.8 months, up from 7.6 months previously. The extension reflects increased diligence requirements and more internal approval layers from corporate buyers. NHS practices requiring the partnership route for contract transfer may take 12 months or longer.

Glossary

Term	Definition
Adjusted EBITDA	Earnings Before Interest, Taxes, Depreciation, and Amortisation, normalised to remove personal expenses, adjust owner compensation to market rates, and deduct the cost of replacing the principal's clinical hours
ARF	Annual Retention Fee; the annual payment made to the GDC to maintain registration, £698 for dentists in 2026
Associate	A self-employed dentist working within a practice, typically paid 40% to 50% of NHS fees and 45% to 55% of private fees generated
Associate Split	The percentage of gross fees paid to a self-employed associate dentist; typically 45% to 55% for private work in the UK
Band 1/2/3	NHS treatment bands in England; Band 1 covers examinations (1 UDA), Band 2 covers fillings and extractions (3 UDAs), and Band 3 covers crowns, dentures, and bridges (12 UDAs)
Capitation Plan	A monthly payment plan (e.g., Denplan, Practice Plan) where patients pay a fixed fee for agreed preventive and treatment benefits; the closest equivalent to recurring revenue in dentistry
CBCT	Cone Beam Computed Tomography; a 3D dental X-ray scanner used for implant planning and complex diagnostic cases
Clawback	Recovery of NHS funding when a practice fails to deliver its contracted UDA target, typically against a 96% delivery threshold
CPOM	Corporate Practice of Medicine (or Dentistry) doctrine; a legal restriction in most US states preventing non-dentist ownership of a clinical practice, the structural reason the DSO model exists
CQC	Care Quality Commission; the independent regulator of health and social care in England; registers but does not rate dental practices
Denplan/Practice Plan	Private dental capitation membership schemes under which patients pay a monthly fee for preventive care and discounted treatment
DSO	Dental Support Organization; a corporate entity providing non-clinical administrative support to dental practices, primarily in the US, structured to comply with corporate practice of dentistry laws
Earn-Out	A portion of the purchase price contingent on the practice meeting specific financial or operational targets post-sale
GDC	General Dental Council; the UK-wide statutory regulator of dental professionals
GDS Contract	General Dental Services contract; the standard NHS contract for primary care dentistry in England
Goodwill	The intangible value of the practice above its tangible asset value; traditionally expressed in UK dentistry as a percentage of gross fee income
HTM 01-05	Health Technical Memorandum outlining decontamination standards in primary care dental practices; non-compliance carries capital expenditure consequences
ICB	Integrated Care Board; the NHS commissioning body responsible for dental contracts in England (replaced Local Area Teams)
IRR17	Ionising Radiation Regulations 2017; governs the safe use of X-ray equipment in dental practices
iTero/Trios	Digital impression scanners that replace traditional physical moulds for crowns, bridges, and orthodontic appliances such as Invisalign
MSA	Management Services Agreement; the contract between a DSO and a Professional Corporation in the US, enabling non-dentist management of clinical practices
NASDAL	National Association of Specialist Dental Accountants and Lawyers; publishes the quarterly Goodwill Survey
PC	Professional Corporation; the dentist-owned clinical entity in US states with corporate practice of dentistry restrictions
Principal	The practice owner, who may also work clinically as a treating dentist
RPA	Radiation Protection Adviser; a qualified expert required under IRR17 to advise on radiation safety and equipment testing
SDE	Seller's Discretionary Earnings; a valuation metric for smaller practices (typically under £250K profit) representing the total financial benefit to a single owner-operator
Squat Practice	A newly built dental practice with no existing patient base or goodwill, established from scratch rather than acquired
UDA	Unit of Dental Activity; the measure by which NHS dental contracts are monitored and paid in England

Methodology and Sources

This guide is built on primary filings, named institutional research with stated methodologies, and DealFlowAgent's proprietary advisory experience (labelled as such where it appears). Due to the strict confidentiality of individual dental practice transactions, we do not publish fabricated or estimated deal values. This is an honest position, not a gap. The dental sector has the weakest deal-value disclosure of any trade we cover, and publishing the gap is more credible than papering over it.

Our valuation ranges are triangulated from the following Tier 1 sources:

Source	Methodology	Coverage
NASDAL Goodwill Survey	Quarterly survey of specialist dental accountant and lawyer members; reports goodwill as % of gross fees	UK, quarterly since 2008
Independent dental goodwill survey 2026	Annual report based on completed UK dental transactions	UK, annual
UK dental market outlook 2026	Based on 1,241 practices advised or sold and 432 RICS valuations in 2025	UK, annual
Group Dentistry Now	Monthly DSO deal roundups tracking partnership and de novo activity	US, monthly
Becker's Dental	Annual DSO directory with scale and activity data	US, annual

Where two sources conflict, both figures are presented with the methodological difference stated. Where DealFlowAgent's own view appears, it is labelled "DealFlowAgent data" or "DealFlowAgent estimate" in the same sentence.

Note: The regulatory and NHS contract frameworks discussed in this guide apply specifically to England. Scotland, Wales, and Northern Ireland operate under different NHS dental contract regimes. Wales implemented a new contract from April 2026. Owners in the devolved nations should seek specialist legal advice on their specific regime.

Related Valuation Guides

Guide	Link
HVAC Valuation Guide	View
Fire Safety Valuation Guide	View
Electrical Valuation Guide	View
Security Systems Valuation Guide	View
Veterinary Practice	View
Medical Clinics	View
Medispas	View
Optometry	View
GP Practices	View
Care Homes	View
Dental Practices for Sale	Current listings
Buy-Side Healthcare Mandates	Active buyer requirements

About DealFlowAgent

DealFlowAgent is a specialist sell-side M&A advisory firm representing owner-led businesses across the UK and US. We maintain an active, pre-qualified network of corporate acquirers, private equity sponsors, and independent groups seeking high-quality assets in healthcare, building services, and facilities management. Our dental practice expertise covers NHS contract transfer mechanics, principal-hour normalisation, and the specific diligence requirements of corporate dental acquirers.

If you advise owners in this trade, whether as an accountant, solicitor, or financial planner, we operate a structured professional referral programme that allows you to remain the trusted adviser while we handle the M&A workstream. Learn more about our adviser network.

To understand how we prepare businesses for a liquidity event, read about our exit readiness methodology or view our current buy-side mandates. For owners ready to explore their options, book a confidential call.

Disclaimer

This guide is for informational purposes only and does not constitute financial, legal, or tax advice. Valuations are indicative and based on market data available at the time of publication. Individual practice valuations depend on specific circumstances. Seek independent professional advice before making any transaction decisions.

Related sector pages and valuation guides

Sector pages for this trade

Every DealFlowAgent valuation guide

Plan your exit